

8 LITERATURVERZEICHNIS

- [1] Akada R, Murakane T & Nishizawa Y (2000). DNA extraction method for screening yeast clones by PCR. *Biotechniques* **28**, 668-670, 672, 674.
- [2] Arbeitsgemeinschaft industrieller Forschungsvereinigungen "Otto von Guericke" e.V. (AiF) (2005). Auf der Medica 2005: Schnelltest entlarvt Zytostatika vor Ort. <http://idw-online.de/pages/en/news134496>. (20.07.2007).
- [3] Arstila TP (2006). Estimating diversity, the easy way. *Nat Methods* **3**, 879-880.
- [4] Arts MJ, Haenen GR, Voss HP & Bast A (2004). Antioxidant capacity of reaction products limits the applicability of the Trolox Equivalent Antioxidant Capacity (TEAC) assay. *Food Chem Toxicol* **42**, 45-49.
- [5] Babendure JR, Adams SR & Tsien RY (2003). Aptamers switch on fluorescence of triphenylmethane dyes. *J Am Chem Soc* **125**, 14716-14717.
- [6] Bachler M, Schroeder R & von Ahsen U (1999). StreptoTag: a novel method for the isolation of RNA-binding proteins. *Rna* **5**, 1509-1516.
- [7] Bagalkot V, Farokhzad OC, Langer R & Jon S (2006). An Aptamer-Doxorubicin Physical Conjugate as a Novel Targeted Drug-Delivery Platform. *Angew Chem Int Ed Engl*. **45**, 8149-8152.
- [8] Baker BR, Lai RY, Wood MS, Doctor EH, Heeger AJ & Plaxco KW (2006). An electronic, aptamer-based small-molecule sensor for the rapid, label-free detection of cocaine in adulterated samples and biological fluids. *J Am Chem Soc* **128**, 3138-3139.
- [9] Baldrich E, Acero JL, Reekmans G, Laureyn W & O'Sullivan CK (2005). Displacement enzyme linked aptamer assay. *Anal Chem* **77**, 4774-4784.
- [10] Baldrich E, Restrepo A & O'Sullivan CK (2004). Aptasensor development: elucidation of critical parameters for optimal aptamer performance. *Anal Chem* **76**, 7053-7063.
- [11] Bang GS, Cho S & Kim BG (2005). A novel electrochemical detection method for aptamer biosensors. *Biosens Bioelectron* **21**, 863-870.
- [12] Bartels A (2002). Durchflußzytometrische Untersuchungen zur zellulären Pharmakokinetik von freiem und liposomal verkapseltem Daunorubicin. *Dissertation*. Humboldt-Universität Berlin.
- [13] Baugh C, Grate D & Wilson C (2000). 2.8 Å crystal structure of the malachite green aptamer. *J Mol Biol* **301**, 117-128.
- [14] Baum PD & McCune JM (2006). Direct measurement of T-cell receptor repertoire diversity with AmpliCot. *Nat Methods* **3**, 895-901.
- [15] Bell SD, Denu JM, Dixon JE & Ellington AD (1998). RNA molecules that bind to and inhibit the active site of a tyrosine phosphatase. *J Biol Chem* **273**, 14309-14314.
- [16] Berens C, Thain A & Schroeder R (2001). A tetracycline-binding RNA aptamer. *Bioorg Med Chem* **9**, 2549-2556.
- [17] Biacore Handbook (2001). An introduction to Biacore's SPR technology, Biacore AB.
- [18] Blind M, Grättinger M & Mayer G (2002). Nucleic acid biotools: accelerating the discovery of lead compounds. *Screening* **6**, 35-37.
- [19] Blount KF & Breaker RR (2006). Riboswitches as antibacterial drug targets. *Nat Biotechnol* **24**, 1558-1564.
- [20] Borbas KE, Ferreira CS, Perkins A, Bruce JI & Missailidis S (2007). Design and Synthesis of Mono- and Multimeric Targeted Radiopharmaceuticals Based on Novel Cyclen Ligands Coupled to Anti-MUC1 Aptamers for the Diagnostic Imaging and Targeted Radiotherapy of Cancer. *Bioconjug Chem* **18**, 1205-1212.
- [21] Bosch I & Croop J (1996). P-glycoprotein multidrug resistance and cancer. *Biochim Biophys Acta* **1288**, F37-54.
- [22] Boven E, de Jong J, Kuiper CM, Bast A & van der Vijgh WJ (1996). Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. *Eur J Cancer* **32A**, 1382-1387.
- [23] Brada D & Roth J (1984). "Golden blot"--detection of polyclonal and monoclonal antibodies bound to antigens on nitrocellulose by protein A-gold complexes. *Anal Biochem* **142**, 79-83.
- [24] Britten RJ & Kohne DE (1968). Repeated sequences in DNA. Hundreds of thousands of copies of DNA sequences have been incorporated into the genomes of higher organisms. *Science* **161**, 529-540.
- [25] Bruno JG & Kiel JL (1999). In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection. *Biosens Bioelectron* **14**, 457-464.

- [26] Burke DH & Gold L (1997). RNA aptamers to the adenosine moiety of S-adenosyl methionine: structural inferences from variations on a theme and the reproducibility of SELEX. *Nucleic Acids Res* **25**, 2020-2024.
- [27] Burke DH & Hoffman DC (1998). A novel acidophilic RNA motif that recognizes coenzyme A. *Biochemistry* **37**, 4653-4663.
- [28] Burke DH, Hoffman DC, Brown A, Hansen M, Pardi A & Gold L (1997). RNA aptamers to the peptidyl transferase inhibitor chloramphenicol. *Chem Biol* **4**, 833-843.
- [29] Burmeister PE, Lewis SD, Silva RF, Preiss JR, Horwitz LR, Pendergrast PS, McCauley TG, Kurz JC, Epstein DM, Wilson C & Keefe AD (2005). Direct in vitro selection of a 2'-O-methyl aptamer to VEGF. *Chem Biol* **12**, 25-33.
- [30] Burmeister PE, Wang C, Killough JR, Lewis SD, Horwitz LR, Ferguson A, Thompson KM, Pendergrast PS, McCauley TG, Kurz M, Diener J, Cload ST, Wilson C & Keefe AD (2006). 2'-Deoxy purine, 2'-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics. *Oligonucleotides* **16**, 337-351.
- [31] Cerchia L, Duconge F, Pestourie C, Boulay J, Aissouni Y, Gombert K, Tavitian B, de Franciscis V & Libri D (2005). Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. *PLoS Biol* **3**, e123.
- [32] Chaires JB, Herrera JE & Waring MJ (1990). Preferential binding of daunomycin to 5'ATCG and 5'ATGC sequences revealed by footprinting titration experiments. *Biochemistry* **29**, 6145-6153.
- [33] Chen KX, Gresh N & Pullman B (1985). A theoretical investigation on the sequence selective binding of daunomycin to double-stranded polynucleotides. *J Biomol Struct Dyn* **3**, 445-466.
- [34] Cheng G-F, Zhao J, Tu Y-H, He P-G & Fang Y-Z (2005). Study on the Interaction between Antitumor Drug Daunomycin and DNA. *Chinese Journal of Chemistry* **23**, 576-580.
- [35] Chu TC, Marks JW, 3rd, Lavery LA, Faulkner S, Rosenblum MG, Ellington AD & Levy M (2006a). Aptamer:toxin conjugates that specifically target prostate tumor cells. *Cancer Res* **66**, 5989-5992.
- [36] Chu TC, Twu KY, Ellington AD & Levy M (2006b). Aptamer mediated siRNA delivery. *Nucleic Acids Res* **34**, e73.
- [37] Clark GR, Pytel PD, Squire CJ & Neidle S (2003). Structure of the first parallel DNA quadruplex-drug complex. *J Am Chem Soc* **125**, 4066-4067.
- [38] Clark JM (1988). Novel non-templated nucleotide addition reactions catalyzed by procaryotic and eucaryotic DNA polymerases. *Nucleic Acids Res* **16**, 9677-9686.
- [39] Connell GJ, Illangsekare M & Yarus M (1993). Three small ribooligonucleotides with specific arginine sites. *Biochemistry* **32**, 5497-5502.
- [40] Corbino KA, Barrick JE, Lim J, Welz R, Tucker BJ, Puskarz I, Mandal M, Rudnick ND & Breaker RR (2005). Evidence for a second class of S-adenosylmethionine riboswitches and other regulatory RNA motifs in alpha-proteobacteria. *Genome Biol* **6**, R70.
- [41] Cox JC & Ellington AD (2001). Automated selection of anti-protein aptamers. *Bioorg Med Chem* **9**, 2525-2531.
- [42] Cox JC, Hayhurst A, Hesselberth J, Bayer TS, Georgiou G & Ellington AD (2002a). Automated selection of aptamers against protein targets translated in vitro: from gene to aptamer. *Nucleic Acids Res* **30**, e108.
- [43] Cox JC, Rajendran M, Riedel T, Davidson EA, Sooter LJ, Bayer TS, Schmitz-Brown M & Ellington AD (2002b). Automated acquisition of aptamer sequences. *Comb Chem High Throughput Screen* **5**, 289-299.
- [44] Cox JC, Rudolph P & Ellington AD (1998). Automated RNA selection. *Biotechnol Prog* **14**, 845-850.
- [45] Cullinane C, Cutts SM, van Rosmalen A & Phillips DR (1994a). Formation of adriamycin--DNA adducts in vitro. *Nucleic Acids Res* **22**, 2296-2303.
- [46] Cullinane C & Phillips DR (1990). Induction of stable transcriptional blockage sites by adriamycin: GpC specificity of apparent adriamycin-DNA adducts and dependence on iron(III) ions. *Biochemistry* **29**, 5638-5646.
- [47] Cullinane C & Phillips DR (1994). Sequence specificity of (cyanomorpholino)adriamycin adducts in human cells. *Biochemistry* **33**, 6207-6212.
- [48] Cullinane C, van Rosmalen A & Phillips DR (1994b). Does adriamycin induce interstrand cross-links in DNA? *Biochemistry* **33**, 4632-4638.
- [49] Cunningham ET, Jr., Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M & Schwartz SD (2005). A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. *Ophthalmology* **112**, 1747-1757.
- [50] Cutts SM, Parsons PG, Sturm RA & Phillips DR (1996). Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase. *J Biol Chem* **271**, 5422-5429.
- [51] Cutts SM & Phillips DR (1995). Use of oligonucleotides to define the site of interstrand cross-links induced by Adriamycin. *Nucleic Acids Res* **23**, 2450-2456.

- [52] Cutts SM, Swift LP, Rephaeli A, Nudelman A & Phillips DR (2003). Sequence specificity of adriamycin-DNA adducts in human tumor cells. *Mol Cancer Ther* **2**, 661-670.
- [53] Dahmen FY (1998). Selektion hochaffiner RNA-Moleküle gegen das Alzheimer beta-Amyloid. *Dissertation*. Freie Universität, Berlin.
- [54] Daniels DA, Chen H, Hicke BJ, Swiderek KM & Gold L (2003). A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. *Proc Natl Acad Sci U S A* **100**, 15416-15421.
- [55] Davis JT (2004). G-quartets 40 years later: from 5'-GMP to molecular biology and supramolecular chemistry. *Angew Chem Int Ed Engl* **43**, 668-698.
- [56] Davis KA, Abrams B, Lin Y & Jayasena SD (1996). Use of a high affinity DNA ligand in flow cytometry. *Nucleic Acids Res* **24**, 702-706.
- [57] Davis KA, Lin Y, Abrams B & Jayasena SD (1998). Staining of cell surface human CD4 with 2'-F-pyrimidine-containing RNA aptamers for flow cytometry. *Nucleic Acids Res* **26**, 3915-3924.
- [58] Davis W, Jr., Ronai Z & Tew KD (2001). Cellular thiols and reactive oxygen species in drug-induced apoptosis. *J Pharmacol Exp Ther* **296**, 1-6.
- [59] de Zwart I, Lozupone C, Knight R, Birmingham A, Illangasekare M, Jadhav V, Legiewicz M, Majerfeld I, Widmann J & Yarus M (2005). Artificial Selection: Finding Function amongst Randomized Sequences. In: *Handbook of RNA Biochemistry*, Ed: R.K. Hartmann, Bindereif, A, Schön, A, Westhof, E, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. pp 783-806.
- [60] Dimarco A, Gaetani M, Dorigotti L, Soldati M & Bellini O (1963). [Experimental Studies of the Antineoplastic Activity of a New Antibiotic, Daunomycin.]. *Tumori* **49**, 203-217.
- [61] Dorr R, Von Hoff DD & Von Hoff DD (1994). *Cancer Chemotherapy Handbook*, Custom edition (January 30, 1994) edn., McGraw-Hill (Tx).
- [62] Dougan H, Lyster DM, Vo CV, Stafford A, Weitz JI & Hobbs JB (2000). Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. *Nucl Med Biol* **27**, 289-297.
- [63] Doyle SA & Murphy MB (2005). Aptamers and methods for their in vitro selection and uses thereof. *WO 2005/024042 A2*.
- [64] Drolet DW, Jayasena SD & Gold L (1998). Enzyme linked oligonucleotide assays (ELONAS). *US005789163A*.
- [65] Drolet DW, Moon-McDermott L & Romig TS (1996). An enzyme-linked oligonucleotide assay. *Nat Biotechnol* **14**, 1021-1025.
- [66] Dubost M, Ganter P, Maral R, Ninet L, Pinnert S, Preudhomme J & Werner GH (1963). [a New Antibiotic with Cytostatic Properties: Rubidomycin.]. *C R Hebd Seances Acad Sci* **257**, 1813-1815.
- [67] Eckel R, Ros R, Ros A, Wilking SD, Sewald N & Anselmetti D (2003). Identification of binding mechanisms in single molecule-DNA complexes. *Biophys J* **85**, 1968-1973.
- [68] Ellington AD & Szostak JW (1990). In vitro selection of RNA molecules that bind specific ligands. *Nature* **346**, 818-822.
- [69] Ellington AD & Szostak JW (1992). Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures. *Nature* **355**, 850-852.
- [70] Elmore LW, Rehder CW, Di X, McChesney PA, Jackson-Cook CK, Gewirtz DA & Holt SE (2002). Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. *J Biol Chem* **277**, 35509-35515.
- [71] Eulberg D, Buchner K, Maasch C & Klussmann S (2005a). Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist. *Nucleic Acids Res* **33**, e45.
- [72] Eulberg D, Maasch C, Purschke WG & Klussmann S (2005b). In vitro Selection against Small Targets. In: *Handbook of RNA Biochemistry*, Ed: R.K. Hartmann, Bindereif, A., Schön, A., Westhof, E., Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. pp 853-877.
- [73] EyetechStudyGroup (2002). Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. *Retina* **22**, 143-152.
- [74] EyetechStudyGroup (2003). Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. *Ophthalmology* **110**, 979-986.
- [75] Famulok M (1994). Molecular Recognition of Amino Acids by RNA-Aptamers: An L-Citrulline binding RNA Motif and Its Evolution into an L-Arginine Binder. *J Am Chem Soc* **116**, 1698-1706.
- [76] Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP & Langer R (2006a). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. *Proc Natl Acad Sci U S A* **103**, 6315-6320.

- [77] Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA & Langer R (2004). Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. *Cancer Res* **64**, 7668-7672.
- [78] Farokhzad OC, Karp JM & Langer R (2006b). Nanoparticle-aptamer bioconjugates for cancer targeting. *Expert Opin Drug Deliv* **3**, 311-324.
- [79] FDA (2004). FDA Approves New Drug Treatment for Age-Related Macular Degeneration. <http://www.fda.gov/bbs/topics/news/2004/new01146.html>. (07.07.2007).
- [80] Fedoroff OY, Salazar M, Han H, Chemeris VV, Kerwin SM & Hurley LH (1998). NMR-Based model of a telomerase-inhibiting compound bound to G-quadruplex DNA. *Biochemistry* **37**, 12367-12374.
- [81] Fenton HJH (1876). On a new reaction of tartaric acid. *Chem. News* **33**, 190.
- [82] Ferguson JA, Boles TC, Adams CP & Walt DR (1996). A fiber-optic DNA biosensor microarray for the analysis of gene expression. *Nat Biotechnol* **14**, 1681-1684.
- [83] Ferreira CS, Matthews CS & Missailidis S (2006). DNA Aptamers That Bind to MUC1 Tumour Marker: Design and Characterization of MUC1-Binding Single-Stranded DNA Aptamers. *Tumour Biol* **27**, 289-301.
- [84] Fialova M, Kyrp J & Vorlickova M (2006). The thrombin binding aptamer GGTTGGTGTGGTTGG forms a bimolecular guanine tetraplex. *Biochem Biophys Res Commun* **344**, 50-54.
- [85] Flinders J, DeFina SC, Brackett DM, Baugh C, Wilson C & Dieckmann T (2004). Recognition of planar and nonplanar ligands in the malachite green-RNA aptamer complex. *ChemBiochem* **5**, 62-72.
- [86] Fogli S, Danesi R, Innocenti F, Di Paolo A, Bocci G, Barbara C & Del Tacca M (1999). An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. *Ther Drug Monit* **21**, 367-375.
- [87] Frezard F, Pereira-Maia E, Quidu P, Priebe W & Garnier-Suillerot A (2001). P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine. *Eur J Biochem* **268**, 1561-1567.
- [88] Frishman WH, Sung HM, Yee HC, Liu LL, Einzig AI, Dutcher J & Keefe D (1996). Cardiovascular toxicity with cancer chemotherapy. *Curr Probl Cardiol* **21**, 225-286.
- [89] Froelich-Ammon SJ & Osheroff N (1995). Topoisomerase poisons: harnessing the dark side of enzyme mechanism. *J Biol Chem* **270**, 21429-21432.
- [90] Fujiwara K, Shin M, Hougaard DM & Larsson LI (2007). Distribution of anticancer antibiotic daunomycin in the rat heart and kidney revealed by immunocytochemistry using monoclonal antibodies. *Histochem Cell Biol* **127**, 69-77.
- [91] Fürhacker M, Lenz K, Mahnik S, Weissenbacher N, Mader R, Knasmüller S, Ferk F, Uhl M, Bursch W, Köllensperger G & Hann S (2006). Chemische Analyse, Risikobewertung und Entfernung von ausgewählten Zytostatika aus Abwasserströmen aus Krankenhäusern, Bundesministerium für Land- und Forstwirtschaft, Umwelt und Wasserwirtschaft (BMLFUW), Wien.
- [92] Gaillard C & Strauss F (1990). Ethanol precipitation of DNA with linear polyacrylamide as carrier. *Nucleic Acids Res* **18**, 378.
- [93] Gallati H (1979). [Horseradish peroxidase: a study of the kinetics and the determination of optimal reaction conditions, using hydrogen peroxide and 2,2'-azinobis 3-ethylbenzthiazoline-6-sulfonic acid (ABTS) as substrates (author's transl)]. *J Clin Chem Clin Biochem* **17**, 1-7.
- [94] Gavathiotis E, Heald RA, Stevens MF & Searle MS (2001). Recognition and Stabilization of Quadruplex DNA by a Potent New Telomerase Inhibitor: NMR Studies of the 2:1 Complex of a Pentacyclic Methylacridinium Cation with d(TTAGGGT)(4) We thank the EPSRC of the UK and AstraZeneca for financial support to E.G. M.F.G.S. and R.A.H. are supported by the Cancer Research Campaign of the UK. *Angew Chem Int Ed Engl* **40**, 4749-4751.
- [95] Gebhardt K, Shokraei A, Babaie E & Lindqvist BH (2000). RNA aptamers to S-adenosylhomocysteine: kinetic properties, divalent cation dependency, and comparison with anti-S-adenosylhomocysteine antibody. *Biochemistry* **39**, 7255-7265.
- [96] Geiger A, Burgstaller P, von der Eltz H, Roeder A & Famulok M (1996). RNA aptamers that bind L-arginine with sub-micromolar dissociation constants and high enantioselectivity. *Nucleic Acids Res* **24**, 1029-1036.
- [97] Gold L, Polisky B, Uhlenbeck O & Yarus M (1995). Diversity of oligonucleotide functions. *Annu Rev Biochem* **64**, 763-797.
- [98] Grate D & Wilson C (1999). Laser-mediated, site-specific inactivation of RNA transcripts. *Proc Natl Acad Sci U S A* **96**, 6131-6136.
- [99] Grate D & Wilson C (2001). Inducible regulation of the *S. cerevisiae* cell cycle mediated by an RNA aptamer-ligand complex. *Bioorg Med Chem* **9**, 2565-2570.
- [100] Gray GD & Wickstrom E (1997). Rapid measurement of modified oligonucleotide levels in plasma samples with a fluorophore specific for single-stranded DNA. *Antisense Nucleic Acid Drug Dev* **7**, 133-140.

- [101] Green LS, Jellinek D, Bell C, Beebe LA, Feistner BD, Gill SC, Jucker FM & Janjic N (1995). Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. *Chem Biol* **2**, 683-695.
- [102] Hamaguchi N, Ellington A & Stanton M (2001). Aptamer beacons for the direct detection of proteins. *Anal Biochem* **294**, 126-131.
- [103] Hanahan D (1983). Studies on transformation of *Escherichia coli* with plasmids. *J Mol Biol* **166**, 557-580.
- [104] Hansen JA, Wang J, Kawde AN, Xiang Y, Gothelf KV & Collins G (2006). Quantum-dot/aptamer-based ultrasensitive multi-analyte electrochemical biosensor. *J Am Chem Soc* **128**, 2228-2229.
- [105] Harada K & Frankel AD (1995). Identification of two novel arginine binding DNAs. *Embo J* **14**, 5798-5811.
- [106] Hartig JS & Famulok M (2002). Reporter ribozymes for real-time analysis of domain-specific interactions in biomolecules: HIV-1 reverse transcriptase and the primer-template complex. *Angew Chem Int Ed Engl* **41**, 4263-4266.
- [107] Hartig JS, Najafi-Shoushtari SH, Grune I, Yan A, Ellington AD & Famulok M (2002). Protein-dependent ribozymes report molecular interactions in real time. *Nat Biotechnol* **20**, 717-722.
- [108] Henderson K & Rogerson A (2003). Detection of pregnancy. *EP20000975030*.
- [109] Hianik T, Ostatna V, Zajacova Z, Stoikova E & Evtugyn G (2005). Detection of aptamer-protein interactions using QCM and electrochemical indicator methods. *Bioorg Med Chem Lett* **15**, 291-295.
- [110] Hicke BJ, Marion C, Chang YF, Gould T, Lynott CK, Parma D, Schmidt PG & Warren S (2001). Tenascin-C aptamers are generated using tumor cells and purified protein. *J Biol Chem* **276**, 48644-48654.
- [111] Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J, Borkowski S, Hilger CS, Cook G, Warren S & Schmidt PG (2006). Tumor targeting by an aptamer. *J Nucl Med* **47**, 668-678.
- [112] Hicke BJ, Watson SR, Koenig A, Lynott CK, Bargatze RF, Chang YF, Ringquist S, Moon-McDermott L, Jennings S, Fitzwater T, Han HL, Varki N, Albinana I, Willis MC, Varki A & Parma D (1996). DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. *J Clin Invest* **98**, 2688-2692.
- [113] Higgins DG & Sharp PM (1989). Fast and sensitive multiple sequence alignments on a microcomputer. *Comput Appl Biosci* **5**, 151-153.
- [114] Ho HA & Leclerc M (2004). Optical sensors based on hybrid aptamer/conjugated polymer complexes. *J Am Chem Soc* **126**, 1384-1387.
- [115] Holeman LA, Robinson SL, Szostak JW & Wilson C (1998). Isolation and characterization of fluorophore-binding RNA aptamers. *Fold Des* **3**, 423-431.
- [116] Holton TA & Graham MW (1991). A simple and efficient method for direct cloning of PCR products using ddT-tailed vectors. *Nucleic Acids Res* **19**, 1156.
- [117] Hu G (1993). DNA polymerase-catalyzed addition of nontemplated extra nucleotides to the 3' end of a DNA fragment. *DNA Cell Biol* **12**, 763-770.
- [118] Huizenga DE & Szostak JW (1995). A DNA aptamer that binds adenosine and ATP. *Biochemistry* **34**, 656-665.
- [119] Huppert JL & Balasubramanian S (2005). Prevalence of quadruplexes in the human genome. *Nucleic Acids Res* **33**, 2908-2916.
- [120] Huppert JL & Balasubramanian S (2007). G-quadruplexes in promoters throughout the human genome. *Nucleic Acids Res* **35**, 406-413.
- [121] Ikebukuro K, Kiyohara C & Sode K (2005). Novel electrochemical sensor system for protein using the aptamers in sandwich manner. *Biosens Bioelectron* **20**, 2168-2172.
- [122] Irvine D, Tuerk C & Gold L (1991). SELEXION. Systematic evolution of ligands by exponential enrichment with integrated optimization by non-linear analysis. *J Mol Biol* **222**, 739-761.
- [123] Jabs T (1999). Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. *Biochem Pharmacol* **57**, 231-245.
- [124] Jarosch F, Buchner K & Klussmann S (2006). In vitro selection using a dual RNA library that allows primerless selection. *Nucleic Acids Res* **34**, e86.
- [125] Jellinek D, Green LS, Bell C, Lynott CK, Gill N, Vargeese C, Kirschenheuter G, McGee DP, Abesinghe P, Pieken WA & et al. (1995). Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. *Biochemistry* **34**, 11363-11372.
- [126] Jenison RD, Gill SC, Pardi A & Polisky B (1994). High-resolution molecular discrimination by RNA. *Science* **263**, 1425-1429.

- [127] Jiang L, Majumdar A, Hu W, Jaishree TJ, Xu W & Patel DJ (1999). Saccharide-RNA recognition in a complex formed between neomycin B and an RNA aptamer. *Structure* **7**, 817-827.
- [128] Joyce GF (1994). In vitro evolution of nucleic acids. *Curr Opin Struct Biol* **4**, 331-336.
- [129] Kalogianni DP, Koraki T, Christopoulos TK & Ioannou PC (2006). Nanoparticle-based DNA biosensor for visual detection of genetically modified organisms. *Biosens Bioelectron* **21**, 1069-1076.
- [130] Kato T, Yano K, Ikebukuro K & Karube I (2000). Interaction of three-way DNA junctions with steroids. *Nucleic Acids Res* **28**, 1963-1968.
- [131] Kemp CJ, Sun S & Gurley KE (2001). p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. *Cancer Res* **61**, 327-332.
- [132] Keohavong P & Thilly WG (1989). Fidelity of DNA polymerases in DNA amplification. *Proc Natl Acad Sci U S A* **86**, 9253-9257.
- [133] Kiga D, Futamura Y, Sakamoto K & Yokoyama S (1998). An RNA aptamer to the xanthine/guanine base with a distinctive mode of purine recognition. *Nucleic Acids Res* **26**, 1755-1760.
- [134] Kikin O, D'Antonio L & Bagga PS (2006). QGRS Mapper: a web-based server for predicting G-quadruplexes in nucleotide sequences. *Nucleic Acids Res* **34**, W676-682.
- [135] Kleinjung F, Klusmann S, Erdmann VA, Scheller FW, Fürste J & Bier F (1998). High-Affinity RNA as a Recognition Element in a Biosensor. *Anal Chem* **70**, 328-331.
- [136] Klusmann S, Nolte A, Bald R, Erdmann VA & Furste JP (1996). Mirror-image RNA that binds D-adenosine. *Nat Biotechnol* **14**, 1112-1115.
- [137] Koizumi M & Breaker RR (2000). Molecular recognition of cAMP by an RNA aptamer. *Biochemistry* **39**, 8983-8992.
- [138] Kovacic P & Osuna JA, Jr. (2000). Mechanisms of anti-cancer agents: emphasis on oxidative stress and electron transfer. *Curr Pharm Des* **6**, 277-309.
- [139] Kretschmann E & Raether H (1968). Radiative decay of non-radiative surface plasmons excited by light. *Z Naturforsch* **23A**, 2135-2136.
- [140] Kubik MF, Bell C, Fitzwater T, Watson SR & Tasset DM (1997). Isolation and characterization of 2'-fluoro-, 2'-amino-, and 2'-fluoro-/amino-modified RNA ligands to human IFN-gamma that inhibit receptor binding. *J Immunol* **159**, 259-267.
- [141] Kwon M, Chun SM, Jeong S & Yu J (2001). In vitro selection of RNA against kanamycin B. *Mol Cells* **11**, 303-311.
- [142] Lachatre F, Marquet P, Ragot S, Gaulier JM, Cardot P & Dupuy JL (2000). Simultaneous determination of four anthracyclines and three metabolites in human serum by liquid chromatography-electrospray mass spectrometry. *J Chromatogr B Biomed Sci Appl* **738**, 281-291.
- [143] Lato SM & Ellington AD (1996). Screening chemical libraries for nucleic-acid-binding drugs by in vitro selection: a test case with lividomycin. *Mol Divers* **2**, 103-110.
- [144] Lauhon CT & Szostak JW (1995). RNA aptamers that bind flavin and nicotinamide redox cofactors. *J Am Chem Soc* **117**, 1246-1257.
- [145] Lee M & Walt DR (2000). A fiber-optic microarray biosensor using aptamers as receptors. *Anal Biochem* **282**, 142-146.
- [146] Lehne G (2000). P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. *Curr Drug Targets* **1**, 85-99.
- [147] Leonard GA, Hambley TW, McAuley-Hecht K, Brown T & Hunter WN (1993). Anthracycline-DNA interactions at unfavourable base-pair triplet-binding sites: structures of d(CGGCCG)/daunomycin and d(TGGCCA)/adriamycin complexes. *Acta Crystallogr D Biol Crystallogr* **49**, 458-467.
- [148] Levy M, Cater SF & Ellington AD (2005). Quantum-dot aptamer beacons for the detection of proteins. *ChemBiochem* **6**, 2163-2166.
- [149] Li JJ, Fang X & Tan W (2002). Molecular aptamer beacons for real-time protein recognition. *Biochem Biophys Res Commun* **292**, 31-40.
- [150] Li Y, Geyer CR & Sen D (1996). Recognition of anionic porphyrins by DNA aptamers. *Biochemistry* **35**, 6911-6922.
- [151] Lin Y, Nieuwlandt D, Magallanez A, Feistner B & Jayasena SD (1996). High-affinity and specific recognition of human thyroid stimulating hormone (hTSH) by in vitro-selected 2'-amino-modified RNA. *Nucleic Acids Res* **24**, 3407-3414.
- [152] Liss M, Petersen B, Wolf H & Prohaska E (2002). An aptamer-based quartz crystal protein biosensor. *Anal Chem* **74**, 4488-4495.
- [153] Liu J, Mazumdar D & Lu Y (2006). A Simple and Sensitive "Dipstick" Test in Serum Based on Lateral Flow Separation of Aptamer-Linked Nanostructures. *Angew Chem Int Ed Engl* **45**, 7955-7959.

- [154] Lorsch JR & Szostak JW (1994). In vitro selection of RNA aptamers specific for cyanocobalamin. *Biochemistry* **33**, 973-982.
- [155] Lothstein L, Israel M & Sweatman TW (2001). Anthracycline drug targeting: cytoplasmic versus nuclear--a fork in the road. *Drug Resist Updat* **4**, 169-177.
- [156] Luce RA, Sigurdsson ST & Hopkins PB (1999). Quantification of formaldehyde-mediated covalent adducts of adriamycin with DNA. *Biochemistry* **38**, 8682-8690.
- [157] Lupold SE, Hicke BJ, Lin Y & Coffey DS (2002). Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. *Cancer Res* **62**, 4029-4033.
- [158] Macaya RF, Schultze P, Smith FW, Roe JA & Feigon J (1993). Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. *Proc Natl Acad Sci U S A* **90**, 3745-3749.
- [159] Mahnik SN, Lenz K, Weissenbacher N, Mader RM & Fuerhacker M (2007). Fate of 5-fluorouracil, doxorubicin, epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bio-reactor system. *Chemosphere* **66**, 30-37.
- [160] Majerfeld I, Puthenvedu D & Yarus M (2005). RNA affinity for molecular L-histidine; genetic code origins. *J Mol Evol* **61**, 226-235.
- [161] Majerfeld I & Yarus M (1994). An RNA pocket for an aliphatic hydrophobe. *Nat Struct Biol* **1**, 287-292.
- [162] Mallikaratchy P, Stahelin RV, Cao Z, Cho W & Tan W (2006). Selection of DNA ligands for protein kinase C-delta. *Chem Commun (Camb)*, 3229-3231.
- [163] Mandal M, Boese B, Barrick JE, Winkler WC & Breaker RR (2003). Riboswitches control fundamental biochemical pathways in *Bacillus subtilis* and other bacteria. *Cell* **113**, 577-586.
- [164] Mandal M & Breaker RR (2004). Adenine riboswitches and gene activation by disruption of a transcription terminator. *Nat Struct Mol Biol* **11**, 29-35.
- [165] Mandal M, Lee M, Barrick JE, Weinberg Z, Emilsson GM, Ruzzo WL & Breaker RR (2004). A glycine-dependent riboswitch that uses cooperative binding to control gene expression. *Science* **306**, 275-279.
- [166] Mann D, Reinemann C, Stoltenburg R & Strehlitz B (2005). In vitro selection of DNA aptamers binding ethanolamine. *Biochem Biophys Res Commun* **338**, 1928-1934.
- [167] Mannironi C, Di Nardo A, Fruscoloni P & Tocchini-Valentini GP (1997). In vitro selection of dopamine RNA ligands. *Biochemistry* **36**, 9726-9734.
- [168] Mannironi C, Scerch C, Fruscoloni P & Tocchini-Valentini GP (2000). Molecular recognition of amino acids by RNA aptamers: the evolution into an L-tyrosine binder of a dopamine-binding RNA motif. *Rna* **6**, 520-527.
- [169] Martell RE, Nevins JR & Sullenger BA (2002). Optimizing aptamer activity for gene therapy applications using expression cassette SELEX. *Mol Ther* **6**, 30-34.
- [170] Mazzini S, Mondelli R & Ragg E (1998). Structure and dynamics of intercalation complexes of anthracyclines with d(CGATCG)₂ and d(CGATACG)₂. 2D-1H and 31P NMR investigations. *Journal of the Chemical Society, Perkin Transactions 2*, **1998**, 1983-1992.
- [171] McCauley TG, Hamaguchi N & Stanton M (2003). Aptamer-based biosensor arrays for detection and quantification of biological macromolecules. *Anal Biochem* **319**, 244-250.
- [172] McNamara JO, 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA & Giangrande PH (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. *Nat Biotechnol* **24**, 1005-1015.
- [173] Meli M, Vergne J, Decout JL & Maurel MC (2002). Adenine-aptamer complexes: a bipartite RNA site that binds the adenine nucleic base. *J Biol Chem* **277**, 2104-2111.
- [174] Mendonsa SD & Bowser MT (2004a). In vitro evolution of functional DNA using capillary electrophoresis. *J Am Chem Soc* **126**, 20-21.
- [175] Mendonsa SD & Bowser MT (2004b). In vitro selection of high-affinity DNA ligands for human IgE using capillary electrophoresis. *Anal Chem* **76**, 5387-5392.
- [176] Mergny JL, Riou JF, Mailliet P, Teulade-Fichou MP & Gilson E (2002). Natural and pharmacological regulation of telomerase. *Nucleic Acids Res* **30**, 839-865.
- [177] Mi J, Zhang X, Rabbani ZN, Liu Y, Su Z, Vujaskovic Z, Kontos CD, Sullenger BA & Clary BM (2006). H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity. *Nucleic Acids Res* **34**, 3577-3584.
- [178] Minotti G, Licata S, Saponiero A, Menna P, Calafiore AM, Di Giammarco G, Liberi G, Animati F, Cipollone A, Manzini S & Maggi CA (2000). Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin,

- epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite. *Chem Res Toxicol* **13**, 1336-1341.
- [179] Minunni M, Tombelli S, Gullotto A, Luzi E & Mascini M (2004). Development of biosensors with aptamers as bio-recognition element: the case of HIV-1 Tat protein. *Biosens Bioelectron* **20**, 1149-1156.
- [180] Mir M, Vreeke M & Katakis I (2006). Different Strategies To Develop an Electrochemical Thrombin Aptasensor. *Electrochemical Communication* **8**, 505-511.
- [181] Moore MH, Hunter WN, d'Estaintot BL & Kennard O (1989). DNA-drug interactions. The crystal structure of d(CGATCG) complexed with daunomycin. *J Mol Biol* **206**, 693-705.
- [182] Mosing RK, Mendonsa SD & Bowser MT (2005). Capillary electrophoresis-SELEX selection of aptamers with affinity for HIV-1 reverse transcriptase. *Anal Chem* **77**, 6107-6112.
- [183] Mülhardt C (2006). *Der Experimentator: Molekularbiologie / Genomics*, 5. Auflage edn., Spektrum Akademischer Verlag, Heidelberg.
- [184] Myers C (1998). The role of iron in doxorubicin-induced cardiomyopathy. *Semin Oncol* **25**, 10-14.
- [185] Nahvi A, Sudarsan N, Ebert MS, Zou X, Brown KL & Breaker RR (2002). Genetic control by a metabolite binding mRNA. *Chem Biol* **9**, 1043.
- [186] Ng EW & Adamis AP (2005). Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. *Can J Ophthalmol* **40**, 352-368.
- [187] Ng EW & Adamis AP (2006). Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. *Ann N Y Acad Sci* **1082**, 151-171.
- [188] Ng EW, Shima DT, Calias P, Cunningham ET, Jr., Guyer DR & Adamis AP (2006). Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. *Nat Rev Drug Discov* **5**, 123-132.
- [189] Nickisch-Hartfiel A (2005). Entwicklung eines immunchromatographischen Wischttests zur schnellen vor Ort Detektion von Zytostatikakontaminationen auf abwischbaren Flächen (Abschlussbericht). Arbeitsgemeinschaft industrieller Forschungsvereinigungen "Otto von Guericke" e.V. (AiF).
- [190] Nieuwlandt D, Wecker M & Gold L (1995). In vitro selection of RNA ligands to substance P. *Biochemistry* **34**, 5651-5659.
- [191] Nolte A, Klusmann S, Bald R, Erdmann VA & Furste JP (1996). Mirror-design of L-oligonucleotide ligands binding to L-arginine. *Nat Biotechnol* **14**, 1116-1119.
- [192] Nutiu R & Li Y (2003). Structure-switching signaling aptamers. *J Am Chem Soc* **125**, 4771-4778.
- [193] Nutiu R & Li Y (2004). Structure-switching signaling aptamers: transducing molecular recognition into fluorescence signaling. *Chemistry* **10**, 1868-1876.
- [194] Olson RD & Mushlin PS (1990). Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. *Faseb J* **4**, 3076-3086.
- [195] Pagratis NC, Bell C, Chang YF, Jennings S, Fitzwater T, Jellinek D & Dang C (1997). Potent 2'-amino-, and 2'-fluoro-2'-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. *Nat Biotechnol* **15**, 68-73.
- [196] Patel DJ, Kozlowski SA & Rice JA (1981a). Hydrogen bonding, overlap geometry, and sequence specificity in anthracycline antitumor antibiotic-DNA complexes in solution. *Proc Natl Acad Sci U S A* **78**, 3333-3337.
- [197] Patel DJ, Kozlowski SA, Rice JA, Broka C & Itakura K (1981b). Mutual interaction between adjacent dG . dC actinomycin binding sites and dA . dT netropsin binding sites on the self-complementary d(C-G-C-G-A-A-T-T-C-G-C-G) duplex in solution. *Proc Natl Acad Sci U S A* **78**, 7281-7284.
- [198] Pavlov V, Xiao Y, Shlyahovsky B & Willner I (2004). Aptamer-functionalized Au nanoparticles for the amplified optical detection of thrombin. *J Am Chem Soc* **126**, 11768-11769.
- [199] Perez-Ruiz T, Martinez-Lozano C, Sanz A & Bravo E (2001). Simultaneous determination of doxorubicin, daunorubicin, and idarubicin by capillary electrophoresis with laser-induced fluorescence detection. *Electrophoresis* **22**, 134-138.
- [200] Perkins AC & Missailidis S (2007). Radiolabelled aptamers for tumour imaging and therapy. *Q J Nucl Med Mol Imaging*.
- [201] Polsky R, Gill R, Kaganovsky L & Willner I (2006). Nucleic acid-functionalized Pt nanoparticles: Catalytic labels for the amplified electrochemical detection of biomolecules. *Anal Chem* **78**, 2268-2271.
- [202] Porstmann B, Porstmann T & Nügel E (1981). Comparison of chromogens for the determination of horseradish peroxidase as a marker in enzyme immunoassay. *J Clin Chem Clin Biochem* **19**, 435-439.
- [203] Possinger K, Hartenstein R & Ehrhart H (1980). [In vitro resistance testing of tumors in relation to cytostatics. 1. Animal experiments]. *Onkologie* **3**, 291-295.

- [204] Possinger K, Wagner H, Worst P, Queisser W, Bremer K, Rieche K, Klee M, Westerhausen M, Donhuijsen-Ant R, Fritze D & et al. (1991). Oral administration of idarubicin as first line cytostatic therapy in patients with metastasized breast cancer and favourable prognosis. A trial of the phase II study group of the Association for Medical Oncology of the German Cancer Society. *Onkologie* **14**, 31-34.
- [205] Potyrailo RA, Conrad RC, Ellington AD & Hietje GM (1998). Adapting selected nucleic acid ligands (aptamers) to biosensors. *Anal Chem* **70**, 3419-3425.
- [206] Purschke WG, Eulberg D, Buchner K, Vonhoff S & Klusmann S (2006). An L-RNA-based aquaretic agent that inhibits vasopressin in vivo. *Proc Natl Acad Sci U S A* **103**, 5173-5178.
- [207] Que-Gewirth NS & Sullenger BA (2007). Gene therapy progress and prospects: RNA aptamers. *Gene Ther* **14**, 283-291.
- [208] Rahman A, Goodman A, Foo W, Harvey J, Smith FP & Schein PS (1984). Clinical pharmacology of daunorubicin in phase I patients with solid tumors: development of an analytical methodology for daunorubicin and its metabolites. *Semin Oncol* **11**, 36-44.
- [209] Rajendran M & Ellington AD (2003). In vitro selection of molecular beacons. *Nucleic Acids Res* **31**, 5700-5713.
- [210] Ravid A, Roker D, Machlenkin A, Rotem C, Hochman A, Kessler-Ickson G, Liberman UA & Koren R (1999). 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. *Cancer Res* **59**, 862-867.
- [211] Reinhoud NJ, Tjaden UR, Irth H & van der Greef J (1992). Bioanalysis of some anthracyclines in human plasma by capillary electrophoresis with laser-induced fluorescence detection. *J Chromatogr* **574**, 327-334.
- [212] Renes J, de Vries EG, Jansen PL & Muller M (2000). The (patho)physiological functions of the MRP family. *Drug Resist Updat* **3**, 289-302.
- [213] Rodriguez MC, Kawde AN & Wang J (2005). Aptamer biosensor for label-free impedance spectroscopy detection of proteins based on recognition-induced switching of the surface charge. *Chem Commun (Camb)*, 4267-4269.
- [214] Roychowdhury-Saha M, Lato SM, Shank ED & Burke DH (2002). Flavin recognition by an RNA aptamer targeted toward FAD. *Biochemistry* **41**, 2492-2499.
- [215] Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L & Janjic N (1998). 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. *J Biol Chem* **273**, 20556-20567.
- [216] Rusconi CP, Roberts JD, Pitoc GA, Nimjee SM, White RR, Quick G, Jr., Scardino E, Fay WP & Sullenger BA (2004). Antidote-mediated control of an anticoagulant aptamer in vivo. *Nat Biotechnol* **22**, 1423-1428.
- [217] Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D & Sullenger BA (2002). RNA aptamers as reversible antagonists of coagulation factor IXa. *Nature* **419**, 90-94.
- [218] Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA & Arnheim N (1985). Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. *Science* **230**, 1350-1354.
- [219] Saito T & Tomida M (2005). Generation of inhibitory DNA aptamers against human hepatocyte growth factor. *DNA Cell Biol* **24**, 624-633.
- [220] Sambrook J & Russell DW (2001). *Molecular Cloning*, 3rd edn., Cold Spring harbor Laboratory Press, New York.
- [221] SantaLucia J, Jr. (1998). A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics. *Proc Natl Acad Sci U S A* **95**, 1460-1465.
- [222] Saran D, Frank J & Burke DH (2003). The tyranny of adenosine recognition among RNA aptamers to coenzyme A. *BMC Evol Biol* **3**, 26.
- [223] Sasanfar M & Szostak JW (1993). An RNA motif that binds ATP. *Nature* **364**, 550-553.
- [224] Sastry CSP & Rao JSVML (1996). Determination of doxorubicin hydrochloride by visible spectrophotometry. *Talanta* **43**, 1827-1835.
- [225] Sazani PL, Larralde R & Szostak JW (2004). A small aptamer with strong and specific recognition of the triphosphate of ATP. *J Am Chem Soc* **126**, 8370-8371.
- [226] Schleyer E, Kuhn S, Ruhrs H, Unterhalt M, Kaufmann CC, Kern W, Braess J, Straubel G & Hiddemann W (1996). Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. *Leukemia* **10**, 707-712.
- [227] Schmidt KS, Borkowski S, Kurreck J, Stephens AW, Bald R, Hecht M, Friebe M, Dinkelborg L & Erdmann VA (2004). Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. *Nucleic Acids Res* **32**, 5757-5765.
- [228] Schreiber C (2002). Einflussfaktoren auf die berufsbedingte Inkorporation von Zytostatika in Klinikapotheken. *Dissertation*. Ludwig-Maximilians-Universität, München.

- [229] Shoji A, Kuwahara M, Ozaki H & Sawai H (2007). Modified DNA aptamer that binds the (R)-isomer of a thalidomide derivative with high enantioselectivity. *J Am Chem Soc* **129**, 1456-1464.
- [230] Siddiqui MA & Keating GM (2005). Pegaptanib: in exudative age-related macular degeneration. *Drugs* **65**, 1571-1577; discussion 1578-1579.
- [231] Simeon N, Chatelut E, Canal P, Nertz M & Couderc F (1999). Anthracycline analysis by capillary electrophoresis. Application to the analysis of daunorubicin in Kaposi sarcoma tumor. *J Chromatogr A* **853**, 449-454.
- [232] Smirnov I & Shafer RH (2000). Effect of loop sequence and size on DNA aptamer stability. *Biochemistry* **39**, 1462-1468.
- [233] Smith CK, Davies GJ, Dodson EJ & Moore MH (1995). DNA-nogalamycin interactions: the crystal structure of d(TGATCA) complexed with nogalamycin. *Biochemistry* **34**, 415-425.
- [234] Srisawat C & Engelke DR (2001). Streptavidin aptamers: affinity tags for the study of RNAs and ribonucleoproteins. *Rna* **7**, 632-641.
- [235] Stojanovic MN, de Prada P & Landry DW (2001). Aptamer-based folding fluorescent sensor for cocaine. *J Am Chem Soc* **123**, 4928-4931.
- [236] Stojanovic MN & Kolpashchikov DM (2004). Modular aptameric sensors. *J Am Chem Soc* **126**, 9266-9270.
- [237] Stojanovic MN & Landry DW (2002). Aptamer-based colorimetric probe for cocaine. *J Am Chem Soc* **124**, 9678-9679.
- [238] Stoltenburg R, Reinemann C & Strehlitz B (2005). FluMag-SELEX as an advantageous method for DNA aptamer selection. *Anal Bioanal Chem* **383**, 83-91.
- [239] Sudarsan N, Wickiser JK, Nakamura S, Ebert MS & Breaker RR (2003). An mRNA structure in bacteria that controls gene expression by binding lysine. *Genes Dev* **17**, 2688-2697.
- [240] Sugawara K, Hirabayashi G, Kamiya N, Kuramitz H & Tanaka S (2005). Evaluation of Binding Between Electroactive Biotin Derivative and Streptavidin Immobilized on Chitin Film. *Electroanalysis* **17**, 1659-1664.
- [241] Sun F, Galas D & Waterman MS (1996). A mathematical analysis of in vitro molecular selection-amplification. *J Mol Biol* **258**, 650-660.
- [242] Taatjes DJ, Gaudiano G & Koch TH (1997a). Production of formaldehyde and DNA-adriamycin or DNA-daunomycin adducts, initiated through redox chemistry of dithiothreitol/iron, xanthine oxidase/NADH/iron, or glutathione/iron. *Chem Res Toxicol* **10**, 953-961.
- [243] Taatjes DJ, Gaudiano G, Resing K & Koch TH (1997b). Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. *J Med Chem* **40**, 1276-1286.
- [244] Tang J, Xie J, Shao N & Yan Y (2006). The DNA aptamers that specifically recognize ricin toxin are selected by two in vitro selection methods. *Electrophoresis* **27**, 1303-1311.
- [245] Tao J & Frankel AD (1996). Arginine-binding RNAs resembling TAR identified by in vitro selection. *Biochemistry* **35**, 2229-2238.
- [246] Thiel K (2004). Oligo oligarchy-the surprisingly small world of aptamers. *Nat Biotechnol* **22**, 649-651.
- [247] Tran-Dinh S, Cavailles JA, Herve M, Neumann JM, Garnier A, Huynh-Dinh T, Langlois d'Estaintot B & Igolen J (1984). 1H-NMR study of the interaction of daunomycin with B-DNA helices of methylated oligodeoxynucleotides. *Nucleic Acids Res* **12**, 6259-6276.
- [248] Trieb M, Rauch C, Wibowo FR, Wellenzohn B & Liedl KR (2004). Cooperative effects on the formation of intercalation sites. *Nucleic Acids Res* **32**, 4696-4703.
- [249] Tuerk C & Gold L (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. *Science* **249**, 505-510.
- [250] van Asperen J, van Tellingen O & Beijnen JH (1998). Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* **712**, 129-143.
- [251] Vant-Hull B, Payano-Baez A, Davis RH & Gold L (1998). The mathematics of SELEX against complex targets. *J Mol Biol* **278**, 579-597.
- [252] Vater A, Jarosch F, Buchner K & Klussmann S (2003). Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX. *Nucleic Acids Res* **31**, e130.
- [253] Vianini E, Palumbo M & Gatto B (2001). In vitro selection of DNA aptamers that bind L-tyrosinamide. *Bioorg Med Chem* **9**, 2543-2548.
- [254] Wade JR, Kelman AW, Kerr DJ, Robert J & Whiting B (1992). Variability in the pharmacokinetics of epirubicin: a population analysis. *Cancer Chemother Pharmacol* **29**, 391-395.

- [255] Wallace ST & Schroeder R (1998). In vitro selection and characterization of streptomycin-binding RNAs: recognition discrimination between antibiotics. *Rna* **4**, 112-123.
- [256] Wallis MG, Streicher B, Wank H, von Ahsen U, Clodi E, Wallace ST, Famulok M & Schroeder R (1997). In vitro selection of a viomycin-binding RNA pseudoknot. *Chem Biol* **4**, 357-366.
- [257] Wallis MG, von Ahsen U, Schroeder R & Famulok M (1995). A novel RNA motif for neomycin recognition. *Chem Biol* **2**, 543-552.
- [258] Wang AH, Ughetto G, Quigley GJ & Rich A (1987). Interactions between an anthracycline antibiotic and DNA: molecular structure of daunomycin complexed to d(CpGpTpApCpG) at 1.2-Å resolution. *Biochemistry* **26**, 1152-1163.
- [259] Wang H, Mao Y, Zhou N, Hu T, Hsieh TS & Liu LF (2001). Atp-bound topoisomerase ii as a target for antitumor drugs. *J Biol Chem* **276**, 15990-15995.
- [260] Wang Y, Killian J, Hamasaki K & Rando RR (1996). RNA molecules that specifically and stoichiometrically bind aminoglycoside antibiotics with high affinities. *Biochemistry* **35**, 12338-12346.
- [261] Wang Y & Rando RR (1995). Specific binding of aminoglycoside antibiotics to RNA. *Chem Biol* **2**, 281-290.
- [262] Weenen H, Lankelma J, Penders PG, McVie JG, ten Bokkel Huinink WW, de Planque MM & Pinedo HM (1983). Pharmacokinetics of 4'-epi-doxorubicin in man. *Invest New Drugs* **1**, 59-64.
- [263] Whatman GmbH (2007). Elutrap system assembly schematic. <http://www.whatman.com/repository/documents/s7/Elutrap%20System%20Ass.pdf>. (24.07.2007).
- [264] White R, Rusconi C, Scardino E, Wolberg A, Lawson J, Hoffman M & Sullenger B (2001). Generation of species cross-reactive aptamers using "toggle" SELEX. *Mol Ther* **4**, 567-573.
- [265] Wiegand TW, Williams PB, Dreskin SC, Jouvin MH, Kinet JP & Tasset D (1996). High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. *J Immunol* **157**, 221-230.
- [266] Wiese L (2001). Interaktion von Doxorubicin und antioxidativen Vitaminen bei den Mammakarzinom-Zelllinien MCF-7 und MDA-MB468. *Dissertation*. Albert-Ludwigs-Universität, Freiburg.
- [267] Wilson C, Nix J & Szostak J (1998). Functional requirements for specific ligand recognition by a biotin-binding RNA pseudoknot. *Biochemistry* **37**, 14410-14419.
- [268] Winkler W, Nahvi A & Breaker RR (2002a). Thiamine derivatives bind messenger RNAs directly to regulate bacterial gene expression. *Nature* **419**, 952-956.
- [269] Winkler WC, Cohen-Chalamish S & Breaker RR (2002b). An mRNA structure that controls gene expression by binding FMN. *Proc Natl Acad Sci U S A* **99**, 15908-15913.
- [270] Winkler WC, Nahvi A, Roth A, Collins JA & Breaker RR (2004). Control of gene expression by a natural metabolite-responsive ribozyme. *Nature* **428**, 281-286.
- [271] Winkler WC, Nahvi A, Sudarsan N, Barrick JE & Breaker RR (2003). An mRNA structure that controls gene expression by binding S-adenosylmethionine. *Nat Struct Biol* **10**, 701-707.
- [272] Wochner A, Cech B, Menger M, Erdmann VA & Glöckler J (2007). Semi-automated selection of DNA aptamers using magnetic particle handling. *Biotechniques* **43**, 344-353.
- [273] Wochner A & Glöckler J (2007). Nonradioactive fluorescence microtiter plate assay monitoring aptamer selections. *Biotechniques* **42**, 578-582.
- [274] Xiao Y, Lubin AA, Heeger AJ & Plaxco KW (2005a). Label-free electronic detection of thrombin in blood serum by using an aptamer-based sensor. *Angew Chem Int Ed Engl* **44**, 5456-5459.
- [275] Xiao Y, Piorek BD, Plaxco KW & Heeger AJ (2005b). A reagentless signal-on architecture for electronic, aptamer-based sensors via target-induced strand displacement. *J Am Chem Soc* **127**, 17990-17991.
- [276] Xu D, Yu X, Liu Z, He W & Ma Z (2005). Label-free electrochemical detection for aptamer-based array electrodes. *Anal Chem* **77**, 5107-5113.
- [277] Yao Y, Wang Q, Hao YH & Tan Z (2007). An exonuclease I hydrolysis assay for evaluating G-quadruplex stabilization by small molecules. *Nucleic Acids Res* **35**, e68.
- [278] Zhang H, Hamasaki A, Toshiro E, Aoyama Y & Ito Y (2000). Automated in vitro selection to obtain functional oligonucleotides. *Nucleic Acids Symp Ser*, 219-220.
- [279] Zimmermann I (2006). Kollaterale Chemosensitivität/-resistenz bei akuten myeloischen Leukämien. *Dissertation*. Ludwig-Maximilians-Universität, München.
- [280] Zuker M (2003). Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res* **31**, 3406-3415.